Skip to main content
Aesthetic Surgery Journal. Open Forum logoLink to Aesthetic Surgery Journal. Open Forum
. 2026 Oct 6;8:ojag195. doi: 10.1093/asjof/ojag195

Inter-Device Agreement Between Vectra H2 and LifeViz Mini for Nasolabial Volumetric Assessment After Thread Lifting: A Post Hoc Method-Comparison Study

Pornsuk Yamlexnoi, Woramate Bhorntarakcharoen, Wilailuck Phokai, Thanakorn Woramongkol, Onjira Meethong, Thitiwat Junpunyawong, Apichaya Jutaphonrakul, Natsuda Sanrit, Anna Sumongkhon, Rungsima Wanitphakdeedecha 1,✉
PMCID: PMC13760621  PMID: 43032580

Abstract

Objective quantification of subtle facial volume change requires reliable 3-dimensional imaging, but measurements from different systems may not be equivalent. The aim of this study was to evaluate agreement between Vectra H2 and LifeViz Mini for nasolabial volumetric assessment after thread lifting.  This post hoc secondary retrospective method-comparison study analyzed paired images prospectively acquired in a parent study. Fifteen women treated with absorbable polydioxanone mesh threads contributed 74 paired side-specific measurements across 43 participant visits. A standardized 1 cm2 nasolabial region of interest was analyzed with Vectra H2 (Canfield Scientific, Inc., Parsippany, NJ) and LifeViz Mini (QuantifiCare S.A., Valbonne, France). Agreement was assessed using an absolute-agreement intraclass correlation coefficient (ICC), Bland–Altman analysis, and paired testing. A participant-level sensitivity analysis averaged bilateral measurements within visits and then averaged visits within each participant. The mean age was 41.87 ± 7.85 years (range, 34-56 years). The paired measurements did not differ significantly (exact 2-sided Wilcoxon P = .356); the median LifeViz Mini-minus-Vectra H2 difference was 0.00108 cm3. The ICC was 0.977 (95% CI, 0.963-0.985). Mean bias was 0.00045 cm3, with limits of agreement from −0.00924 to 0.01013 cm3. Participant-level findings were consistent (P = .804; ICC = 0.953; mean bias, 0.00019 cm3). Vectra H2 and LifeViz Mini produced highly concordant nasolabial volume-change measurements under standardized conditions. The participant-level sensitivity analysis supported the robustness of the findings, although larger prospective studies are required.

Level of Evidence: 3 (Diagnostic)

graphic file with name ojag195il1.jpg


In aesthetic and dermatologic practice, imaging is a pivotal tool for clinical documentation, treatment planning, patient communication, follow-up, and objective outcome assessment. Standardized clinical photography remains essential because it provides a visual record of baseline appearance and posttreatment change; however, 2-dimensional (2D) photography is highly dependent on lighting, camera settings, lens selection, background, head position, and patient expression, all of which can alter the perceived appearance of skin texture and facial contour.1,2 Therefore, 3-dimensional (3D) surface imaging has emerged as a noninvasive method for objective evaluation of facial morphology and treatment outcomes. By reconstructing the skin surface and allowing registration or superimposition of serial images, 3D systems can quantify changes in contour, surface area, and volume, offering advantages over conventional 2D assessment for clinical research and aesthetic outcome evaluation.3,4

Validation studies in aesthetic, reconstructive, and dermatologic surgery support the feasibility of 3D imaging as an objective measurement tool. In breast surgery, LifeViz-based 3D imaging has been evaluated as a feasible and portable method for volumetric assessment, although operator-dependent contouring and region definition remain important considerations.5 Makram et al further demonstrated strong agreement between LifeViz 3D volumetry and magnetic resonance imaging for breast volume assessment, with no statistically significant difference between methods, supporting its clinical use as an objective volumetric tool.6 Portable 3D systems have also been used to detect small volume changes after fat grafting or injectable treatment in the face and other body regions, with good accuracy and reproducibility for changes in the range of a few cubic centimeters.7 Similarly, Vectra-based imaging has been validated for quantitative upper-limb volume measurement in patients with lymphedema, showing high correlation with circumference and water-displacement methods while enabling localized regional measurement.8 More recent studies of the portable Vectra H2 system have demonstrated good reliability for periocular anthropometry, supporting its potential use in small facial regions where measurement precision is essential.9 In addition, portable 3D volumetric systems have shown reliable and accurate measurement of small periorbital objects, suggesting clinical potential for postoperative evaluation and long-term follow-up of regional facial volume changes.10 Beyond aesthetic surgery, 3D imaging has also been validated for dermatologic applications, including venous leg ulcer area measurement and objective quantification of atrophic acne scarring, indicating that 3D systems can provide repeatable and objective measurements across different skin and soft-tissue conditions.11,12

Measurements obtained from different 3D platforms cannot automatically be considered interchangeable because acquisition geometry, reconstruction algorithms, registration, region-of-interest (ROI) placement, and software calculations may differ. Comparative evidence remains limited, and volume measurements may be more variable than linear or surface-area measurements.13 No previous study has specifically evaluated agreement between LifeViz Mini and Vectra H2 for a small nasolabial ROI after thread lifting. The paired datasets in the parent study, therefore, provided an opportunity to assess whether future research could select 1 platform for volumetric analysis rather than routinely acquiring and processing images with both systems. Agreement was evaluated in this standardized setting rather than to establish unrestricted interchangeability across all facial regions or clinical applications.14,15

METHODS

Study Design and Setting

This study was a post hoc secondary retrospective method-comparison analysis of paired 3D images prospectively acquired between July and December 2023 during an ethics-approved parent clinical study of absorbable polydioxanone (PDO) mesh thread lifting (Siriraj Institutional Review Board [SIRB] Protocol No. 410/2566 [IRB2]; approval date, July 26, 2023). Dual-device image acquisition was specified in the parent protocol because the systems provided complementary functions: LifeViz Mini facilitated visualization of facial displacement and lifting vectors, whereas Vectra H2 was used for higher-resolution clinical documentation within the study workflow. Inter-device agreement was not a prespecified objective of the parent study. The present analysis was separately approved by the SIRB (Protocol No. 020/2569 [IRB1]; approval date, March 13, 2026). Data extraction and analysis were performed from March 14 to April 30, 2026 at the Siriraj Skin Laser Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. All participants provided written informed consent before enrollment in the parent study, and only data from consenting participants were included in the present analysis. All data were de-identified, and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

Source images were prospectively acquired between July and December 2023 under SIRB Protocol No. 410/2566 (IRB2; approved July 26, 2023). The present post hoc secondary retrospective method-comparison analysis was approved separately under SIRB Protocol No. 020/2569 (IRB1; approved March 13, 2026). Data extraction and analysis were performed from March 14 to April 30, 2026.

Participants

The parent study enrolled 25 adults who underwent PDO mesh thread lifting for mid-lower facial laxity. The present analysis included 15 participants with at least one analyzable matched side-specific volume-change measurement from both Vectra H2 and LifeViz Mini at the same follow-up visit. Ten parent-study participants were not included because no analyzable paired measurement was available in the method-comparison dataset.

Thread-Lift Procedure and Imaging Schedule

Participants underwent mid-lower facial lifting with absorbable PDO mesh sutures (Tesslift Soft; TESS [Tissue Engineering Scaffolds System], Seoul, South Korea). Four to 5 threads per side were placed in the subcutaneous plane along individualized oblique suspension vectors. Standardized 3D images were acquired at baseline and immediately after treatment, and at 1 week, 1 month, 3 months, and 6 months. The present analysis included all available matched measurements from the 5 posttreatment visits.

Outcomes

The primary outcome was agreement between Vectra H2 and LifeViz Mini measurements of change from baseline in nasolabial volume. Agreement was characterized by the absolute-agreement intraclass correlation coefficient (ICC), Bland–Altman bias and limits of agreement (LoA), and paired comparison of device measurements. The study evaluated device agreement rather than thread-lifting efficacy.

Measurements

Images were acquired during the same session with Vectra H2 (Canfield Scientific, Inc., Parsippany, NJ; software version 7.11) and 3D LifeViz Mini (QuantifiCare S.A., Valbonne, France; LifeVizApp Version 3.15.29.0). The same trained operator performed all acquisitions. Participants maintained a neutral expression, relaxed lips, and standardized head position; hair, cosmetics, and obstructing objects were removed. Volume values were recorded in cubic centimeters; values displayed in milliliters were numerically equivalent because 1 mL equals 1 cm3.

For Vectra H2, right-oblique, frontal, and left-oblique captures were reconstructed into a single 3D facial surface. For LifeViz Mini, standardized central and oblique captures, with an additional under-front view when required, were reconstructed in the LifeVizApp. Baseline and follow-up surfaces were registered separately within each manufacturer-specific software platform.

The ROI was a standardized 1 cm2 triangular area centered on the clinically prominent nasolabial crease between the alar base and ipsilateral oral commissure. The ROI was aligned parallel to the fold and reproduced using the alar base, subnasale, oral commissure, and visible crease as fixed landmarks. This small ROI was selected deliberately as a stringent, clinically relevant model: expected treatment-related changes were subtle, so agreement required the devices to provide concordant measurements in a low-signal and technically challenging region. Larger lateral cheek or jawline regions were not used because their contour changes were more dependent on individualized thread vectors and could introduce treatment–response variability unrelated to device performance.

Vectra H2 images were analyzed with the Vectra Analysis Module. Each follow-up surface was registered to baseline, the predefined ROI was applied, and the volume-difference tool calculated change from baseline.

LifeViz Mini images were analyzed with the LifeVizApp 3D Track function. Baseline and follow-up surfaces were registered using the same anatomical landmarks, the corresponding ROI was selected, and before–after volume change was calculated (Figure 1). Positive values represented increased surface projection relative to baseline.

Figure 1.

Representative matched 1-month analysis of right nasolabial volume change in a 35-year-old woman using a standardized 1 cm2 triangular region of interest (ROI). (A) LifeViz Mini showing a total volume change of 0.0429 cm3 (displayed as 0.043 mL). (B) Vectra H2 showing the corresponding volume change of 0.04679 cm3 (rounded to 0.047 cm3). Both measurements were obtained from the same participant, visit, facial side, and anatomical ROI. Written informed consent for publication of these images was obtained from the participant.

Representative matched 1-month analysis of right nasolabial volume change in a 35-year-old woman using a standardized 1 cm2 triangular region of interest (ROI). (A) LifeViz Mini showing a total volume change of 0.0429 cm3 (displayed as 0.043 mL). (B) Vectra H2 showing the corresponding volume change of 0.04679 cm3 (rounded to 0.047 cm3). Both measurements were obtained from the same participant, visit, facial side, and anatomical ROI. Written informed consent for publication of these images was obtained from the participant.

Measurements were paired by participant, visit, and facial side. Cross-device image fusion was not performed, and the investigator could not be blinded to the device because the software platforms were device-specific. The analytic dataset contained 74 paired side-specific measurements from 43 participant visits nested within 15 participants; therefore, analyses using all 74 measurements were regarded as exploratory.

Sample Size

The sample size was determined by the availability of analyzable paired images from the parent study and was intended to provide preliminary evidence of inter-device agreement.

Statistical Analysis

Statistical analyses were performed with IBM SPSS Statistics, version 29.0 (IBM Corp., Armonk, NY). Device measurements were compared with the exact 2-sided Wilcoxon matched-pairs signed-rank test. Agreement was evaluated using a single-measure ICC from a 2-way mixed-effects model with absolute agreement and Bland–Altman analysis. Differences were defined as LifeViz Mini minus Vectra H2. Bland–Altman estimates included mean bias, 95% LoA, and ∼95% CIs for the bias and LoA. A difference of 0.01 cm3 was used only as a descriptive reference because no validated minimal clinically important difference exists for this 1 cm2 ROI; it corresponds to an average surface displacement of ∼0.1 mm. Because side-specific measurements and serial visits were nested within participants, all 74-observation estimates were interpreted descriptively. An additional participant-level sensitivity analysis first averaged left and right measurements within each visit and then averaged visits within each participant, yielding 1 paired value per participant (n = 15). The sensitivity analysis repeated the Wilcoxon test, ICC, and Bland–Altman calculations. A 2-sided P-value of <.05 was considered statistically significant.15,16

RESULTS

Of 25 participants in the parent study, 15 women had analyzable paired images and were included. Their mean age was 41.87 ± 7.85 years (range, 34-56 years). The dataset contained 74 paired side-specific measurements across 43 participant visits (39 left and 35 right nasolabial measurements). Baseline characteristics are shown in Table 1.

Table 1.

Baseline Characteristics of Study Participants

Characteristic Value
Number of participants 15
Sex, n (%)
 Female 15 (100.0)
Age, years
 Mean ± SD 41.87 ± 7.85
 Range 34-56
Fitzpatrick skin type, n (%)
 Type III 2 (13.3)
 Type IV 12 (80.0)
 Type V 1 (6.7)

SD, standard deviation.

The 74 paired measurements did not differ significantly between devices (exact 2-sided Wilcoxon P = .356). The median difference, defined as LifeViz Mini minus Vectra H2, was 0.00108 cm3.

The single-measure absolute-agreement ICC was 0.977 (95% CI, 0.963-0.985), indicating excellent agreement. The exploratory scatterplot showed a regression equation of LifeViz Mini = 0.00054 + 0.997(Vectra H2), with R2 = 0.954 and Pearson r = 0.977 (Figure 2).

Figure 2.

Relationship between Vectra H2 and LifeViz Mini nasolabial volume-change measurements. The scatterplot includes 74 paired side-specific measurements. The dashed line is the line of identity, and the solid line is the exploratory least-squares regression line. LifeViz Mini = 0.00054 + 0.997 (Vectra H2); R2 = 0.954; Pearson r = 0.977. Repeated observations were contributed by the same participants, so correlation statistics are descriptive.

Relationship between Vectra H2 and LifeViz Mini nasolabial volume-change measurements. The scatterplot includes 74 paired side-specific measurements. The dashed line is the line of identity, and the solid line is the exploratory least-squares regression line. LifeViz Mini = 0.00054 + 0.997 (Vectra H2); R2 = 0.954; Pearson r = 0.977. Repeated observations were contributed by the same participants, so correlation statistics are descriptive.

Bland–Altman analysis of all 74 paired measurements showed a mean bias of 0.00045 cm3 (approximate 95% CI, −0.00069 to 0.00159 cm3), with 95% LoA from −0.00924 to 0.01013 cm3. Approximate 95% CIs were −0.01122 to −0.00726 cm3 for the lower LoA and 0.00815 to 0.01211 cm3 for the upper LoA (Figure 3). Thus, most inter-device differences were within approximately ±0.01 cm3 under the standardized study conditions.

Figure 3.

Bland–Altman analysis of agreement between Vectra H2 and LifeViz Mini nasolabial volume-change measurements. The x-axis represents the mean of paired device measurements (cm3), and the y-axis represents LifeViz Mini minus Vectra H2 (cm3). The solid line indicates the mean bias (0.00045 cm3), and the dashed lines indicate the 95% limits of agreement (LoA; −0.00924 to 0.01013 cm3). The plot contains 74 paired side-specific measurements.

Bland–Altman analysis of agreement between Vectra H2 and LifeViz Mini nasolabial volume-change measurements. The x-axis represents the mean of paired device measurements (cm3), and the y-axis represents LifeViz Mini minus Vectra H2 (cm3). The solid line indicates the mean bias (0.00045 cm3), and the dashed lines indicate the 95% limits of agreement (LoA; −0.00924 to 0.01013 cm3). The plot contains 74 paired side-specific measurements.

In the participant-level sensitivity analysis (n = 15), the Wilcoxon test remained nonsignificant (P = .804), the ICC remained high (0.953), and the mean LifeViz Mini-minus-Vectra H2 difference was 0.00019 cm3 (95% CI, −0.00128 to 0.00165 cm3), with LoA from −0.00501 to 0.00538 cm3. These results supported the robustness of the primary findings when each participant contributed equal weight (Figure 4).

Figure 4.

Serial clinical and volumetric analysis images obtained with LifeViz Mini and Vectra H2 from the same 37-year-old woman with Fitzpatrick skin type IV at selected follow-up visits. Panels are arranged chronologically from upper left to lower right; within each panel, LifeViz Mini is shown on the left and Vectra H2 on the right. (A) At 1 week after treatment, the nasolabial volume-change values were 0.032 and 0.028 cm3, respectively. (B) At 1 month after treatment, the values were 0.032 and 0.031 cm3, respectively. (C) At 3 months after treatment, the values were 0.027 and 0.025 cm3, respectively. (D) At 6 months after treatment, the values were 0.019 and 0.017 cm3, respectively. Values displayed in milliliters are numerically equivalent to cubic centimeters. Written informed consent for publication of these images was obtained from the participant.

Serial clinical and volumetric analysis images obtained with LifeViz Mini and Vectra H2 from the same 37-year-old woman with Fitzpatrick skin type IV at selected follow-up visits. Panels are arranged chronologically from upper left to lower right; within each panel, LifeViz Mini is shown on the left and Vectra H2 on the right. (A) At 1 week after treatment, the nasolabial volume-change values were 0.032 and 0.028 cm3, respectively. (B) At 1 month after treatment, the values were 0.032 and 0.031 cm3, respectively. (C) At 3 months after treatment, the values were 0.027 and 0.025 cm3, respectively. (D) At 6 months after treatment, the values were 0.019 and 0.017 cm3, respectively. Values displayed in milliliters are numerically equivalent to cubic centimeters. Written informed consent for publication of these images was obtained from the participant.

DISCUSSION

The principal finding of this preliminary study was that Vectra H2 and LifeViz Mini produced highly concordant volume-change measurements within a standardized 1 cm2 nasolabial ROI. The ICC was 0.977, the median paired difference was 0.00108 cm3, and the mean bias was 0.00045 cm3. Importantly, a participant-level sensitivity analysis that gave equal weight to each participant yielded consistent results (P = .804; ICC = 0.953; mean bias, 0.00019 cm3).

The Bland–Altman LoA of approximately −0.009 to 0.010 cm3 represents the empirical inter-device disagreement observed in this setting. For a 1 cm2 ROI, 0.01 cm3 corresponds to an average surface displacement of ∼0.1 mm. This magnitude is small in absolute terms and supports close numerical comparability; however, it should not be interpreted as a universal minimal detectable change because no validated clinical acceptance threshold exists for this ROI. Correlation alone does not establish agreement, so the ICC, paired comparison, Bland–Altman analysis, and participant-level sensitivity analysis were interpreted together.

The results are consistent with validation studies showing reliable 3D assessment of facial and soft-tissue morphology.3,7,9,11-13,17 Previous studies have also emphasized that volumetric measurements in small facial regions may be more variable than linear or surface-area measures, supporting device- and ROI-specific evaluation.13,17 The present findings extend this literature by directly comparing Vectra H2 and LifeViz Mini in a small nasolabial ROI.

Accurate registration and ROI reproduction are particularly important when expected changes are small. In this study, baseline and follow-up surfaces were matched with fixed facial landmarks before the ROI was applied. Standardized acquisition and a single trained investigator reduced variability, but manual ROI confirmation remained necessary, and interobserver reproducibility was not evaluated.

The nasolabial fold was selected as a deliberately challenging clinical model. Thread lifting generally produces larger contour changes in the jawline, submental region, and lateral lower face, whereas nasolabial changes are more localized. Demonstrating concordance in this low-signal region provides a stringent assessment of device agreement while minimizing variability related to individualized suspension vectors. The results should not be extrapolated to larger facial regions without further validation.

The practical motivation for the analysis was to determine whether routine dual-device volumetric acquisition was necessary. Although the systems served complementary purposes in the parent study, both quantified volume change. The observed agreement suggests that future studies with similar nasolabial outcomes may select either platform for volumetric assessment according to image quality, vector-visualization needs, availability, and workflow, thereby avoiding duplicate acquisition and processing. Once a platform is selected, consistent use throughout a longitudinal protocol remains sensible for operational standardization rather than because a material systematic difference was demonstrated between the devices.

Limitations

Limitations include the small all-female cohort, predominance of Fitzpatrick skin type IV, restriction to 1 nasolabial ROI, absence of an independent reference standard, and lack of intra-device repeatability and interobserver ROI-placement testing. The primary dataset included bilateral and serial observations that were not statistically independent; the participant-level sensitivity analysis reduced this concern but could not replace a repeated-measures agreement study designed prospectively. The agreement analysis was also post hoc and was not prespecified in the parent protocol. Future prospective studies should include larger and more diverse samples, multiple operators, repeatability testing, clustered agreement models, additional facial ROIs, and reference-standard validation.

CONCLUSIONS

Under standardized acquisition and analysis conditions, Vectra H2 and LifeViz Mini produced highly concordant measurements of nasolabial volume change after PDO mesh thread lifting. The participant-level sensitivity analysis corroborated the primary findings and provides preliminary support for using either system for comparable volumetric assessment in similar research settings. These results require confirmation in larger prospective studies.

Acknowledgments

The authors gratefully acknowledge Suthipol Udompunturak for statistical analysis. During preparation of this work, the authors used ChatGPT (OpenAI, San Francisco, CA) to assist with English-language editing. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Disclosures

The authors have no conflicts of interest to declare. None of the authors has had a financial relationship with Canfield Scientific, Inc. (Canfield Scientific, Inc., Parsippany, NJ) or QuantifiCare S.A. (Valbonne, France) during the 36 months preceding submission. Neither device manufacturer provided equipment, funding, technical assistance, data analysis, writing support, or other support for the present analysis.

Funding

The present post hoc method-comparison analysis received no specific funding. The parent clinical study was an investigator-initiated trial. Rich Aesthetics Thailand (Chiang Mai, Thailand), which was listed as the research sponsor in the parent-study ethics documents, provided the study product (Tesslift Soft absorbable polydioxanone mesh sutures) as in-kind support only and had no role in study design; participant recruitment; data collection, management, analysis, or interpretation; manuscript preparation or review; journal selection; or the decision to submit.

REFERENCES

  • 1. Khavkin  J, Ellis  DA. Standardized photography for skin surface. Facial Plast Surg Clin North Am. 2011;19:241–246. doi: 10.1016/j.fsc.2011.04.001 [DOI] [PubMed] [Google Scholar]
  • 2. Muñoz  G, Brito  L, Olate  S. Photographic parameters in three-dimensional facial image acquisition. A scoping review. J Craniofac Surg. 2024;35:e376–e380. doi: 10.1097/SCS.0000000000010120 [DOI] [PubMed] [Google Scholar]
  • 3. Camison  L, Bykowski  M, Lee  WW, et al.  Validation of the Vectra H1 portable three-dimensional photogrammetry system for facial imaging. Int J Oral Maxillofac Surg. 2018;47:403–410. doi: 10.1016/j.ijom.2017.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Maal  TJ, van Loon  B, Plooij  JM, et al.  Registration of 3-dimensional facial photographs for clinical use. J Oral Maxillofac Surg. 2010;68:2391–2401. doi: 10.1016/j.joms.2009.10.017 [DOI] [PubMed] [Google Scholar]
  • 5. Hoeffelin  H, Jacquemin  D, Defaweux  V, Nizet  JL. A methodological evaluation of volumetric measurement techniques including three-dimensional imaging in breast surgery. Biomed Res Int. 2014;2014:573249. doi: 10.1155/2014/573249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Makram  M, Noaman  A, Abozeid  MD. 3D volume assessment as an objective tool in breast asymmetry management. Plast Reconstr Surg Glob Open. 2023;11:e4904. doi: 10.1097/GOX.0000000000004904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Almadori  A, Speiser  S, Ashby  I, et al.  Portable three-dimensional imaging to monitor small volume enhancement in face, vulva, and hand: a comparative study. J Plast Reconstr Aesthet Surg. 2022;75:3574–3585. doi: 10.1016/j.bjps.2022.04.042 [DOI] [PubMed] [Google Scholar]
  • 8. Landau  MJ, Kim  JS, Gould  DJ, Patel  KM. Vectra 3D imaging for quantitative volumetric analysis of the upper limb: a feasibility study for tracking outcomes of lymphedema treatment. Plast Reconstr Surg. 2018;141:80e–84e. doi: 10.1097/PRS.0000000000003912 [DOI] [PubMed] [Google Scholar]
  • 9. Fan  W, Guo  Y, Hou  X, et al.  Validation of the portable next-generation VECTRA H2 3D imaging system for periocular anthropometry. Front Med (Lausanne). 2022;9:833487. doi: 10.3389/fmed.2022.833487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Zhang  X, Shao  J, Dai  N, et al.  Validation of a portable three-dimensional imaging system for volumetric measurement in the periorbital region. Front Med (Lausanne). 2025;12:1647489. doi: 10.3389/fmed.2025.1647489 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Chaby  G, Lok  C, Thirion  JP, Lucien  A, Senet  P. Three-dimensional digital imaging is as accurate and reliable to measure leg ulcer area as transparent tracing with digital planimetry. J Vasc Surg Venous Lymphat Disord. 2017;5:837–843. doi: 10.1016/j.jvsv.2017.05.019 [DOI] [PubMed] [Google Scholar]
  • 12. Petit  L, Zugaj  D, Bettoli  V, et al.  Validation of 3D skin imaging for objective repeatable quantification of severity of atrophic acne scarring. Skin Res Technol. 2018;24:542–550. doi: 10.1111/srt.12464 [DOI] [PubMed] [Google Scholar]
  • 13. Lau  JCL, Fleming  J, Good  M, et al.  Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with neurofibromatosis type 1. Skin Res Technol. 2024;30:e70020. doi: 10.1111/srt.70020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Bland  JM, Altman  DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–310. doi: 10.1016/S0140-6736(86)90837-8 [DOI] [PubMed] [Google Scholar]
  • 15. Koo  TK, Li  MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155–163. doi: 10.1016/j.jcm.2016.02.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Bland  JM, Altman  DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17:571–582. doi: 10.1080/10543400701329422 [DOI] [PubMed] [Google Scholar]
  • 17. Fan  W, Rokohl  AC, Maus  J, et al.  Evaluation of the portable next-generation VECTRA H2 3D imaging system for measuring upper eyelid area and volume. Aesthet Surg J. 2023;43:1114–1123. doi: 10.1093/asj/sjad136 [DOI] [PubMed] [Google Scholar]

Articles from Aesthetic Surgery Journal. Open Forum are provided here courtesy of Oxford University Press

RESOURCES